Basic Information
| LncRNA/CircRNA Name | LINC00993 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000235687 |
| Refseq | NR_104061 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qRT-PCR, Western blot |
| Sample | breast cancer cell line MDA-MB-231 and BT-549 |
| Expression Pattern | down-regulated |
| Function Description | LINC00993 was largely downregulated in TNBC, and higher expression indicated better outcome. LINC00993 located mainly in the nucleus. LINC00993 suppressed TNBC growth both in vitro and in vivo. LINC00993 was predicted to be involved in cell cycle pathways by using "guilt by association" and GSEA methods. Key cell cycle regulators like p16INK4A, p14ARF, p53, and p21 were affected by LINC00993 overexpression. |
| Pubmed ID | 31921620 |
| Year | 2019 |
| Title | Novel Breast-Specific Long Non-coding RNA LINC00993 Acts as a Tumor Suppressor in Triple-Negative Breast Cancer |
External Links
| Links for LINC00993 | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |